A record of what Jefferies Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Upgraded Gland Pharma to Hold with a price target of ₹1,970, believing earnings have bottomed out, driven by a turnaround in Cenexi and higher-value projects. However, current valuations leave little upside despite a maintained mid-teens revenue growth guidance and increased FY26-27 EPS estimates by 2-5%.”
Jefferies Analysis’s track record (trackable calls only): 153 graded calls · 95% CI 37–53%
Gland Pharma LtdNeutralCalled 06 Aug 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Jefferies Analysis’s full track record